The groups spend big on Terns and Arcellx.
ApexOnco Front Page
Recent articles
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
Artios, Synnovation and Novartis show mere glimmers of activity.
Imfinzi and sasanlimab look nearly identical, but it’s a different story for Roche’s Tecentriq.
The company reveals the first overall survival data in adjuvant ER-positive breast cancer.
Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.
A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.
The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.
